Chevy Chase Trust Holdings LLC Sells 2,244 Shares of DexCom, Inc. (NASDAQ:DXCM)

Chevy Chase Trust Holdings LLC lessened its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,586 shares of the medical device company’s stock after selling 2,244 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in DexCom were worth $29,624,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of DexCom by 41.9% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 10,620 shares of the medical device company’s stock valued at $1,473,000 after purchasing an additional 3,137 shares in the last quarter. RiverPark Advisors LLC bought a new stake in DexCom in the 1st quarter valued at approximately $55,000. Comprehensive Financial Consultants Institutional Inc. bought a new stake in DexCom in the 1st quarter valued at approximately $780,000. Jennison Associates LLC lifted its stake in DexCom by 2.7% in the 1st quarter. Jennison Associates LLC now owns 388,302 shares of the medical device company’s stock valued at $53,858,000 after acquiring an additional 10,217 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in DexCom by 8.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 61,500 shares of the medical device company’s stock valued at $8,530,000 after acquiring an additional 4,775 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.1 %

Shares of DXCM stock traded up $0.15 on Wednesday, hitting $110.99. The company had a trading volume of 993,108 shares, compared to its average volume of 2,886,575. The stock’s 50-day moving average is $120.40 and its two-hundred day moving average is $125.22. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The firm has a market cap of $44.14 billion, a P/E ratio of 71.51, a P/E/G ratio of 2.71 and a beta of 1.16. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, equities research analysts anticipate that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the transaction, the executive vice president now owns 66,901 shares in the company, valued at $7,646,115.29. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders sold 6,102 shares of company stock valued at $755,103 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on DXCM shares. UBS Group boosted their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price on the stock. Citigroup boosted their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Canaccord Genuity Group boosted their target price on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a report on Friday, April 26th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.33.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.